REG - Futura Medical PLC - Remuneration of Non-Exec Directors & Voting Rights

Futura MedicalAnnouncement

17/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240117:nRSQ8992Za&default-theme=true

RNS Number : 8992Z  Futura Medical PLC  17 January 2024

Futura Medical plc

("Futura" or the "Company")

Remuneration of Non-Executive Directors and Total Voting Rights

 

17 January 2024

 

Futura Medical plc (AIM: FUM) (the "Company"), the pharmaceutical company
developing innovative sexual health products, announces the issue of 43,500
new ordinary shares of 0.2 pence each ("Ordinary Shares") in respect of the
2023 remuneration of its Non-Executive Directors.

 

Remuneration of Non-Executive Directors

 

In accordance with the terms of their service agreements, the Non-Executive
Directors receive 25 per cent of their remuneration in the form of Ordinary
Shares which are usually  in January following the period end. For 2023,
these were issued at 51.50 pence per share, being the average closing
mid-market price of the last 10 trading days of 2022 (as announced via RNS on
12 January 2023).

 

The 43,500 new Ordinary Shares shall rank pari passu with the existing issued
Ordinary Shares of the Company and have been issued to the following
Non-Executive Directors:

 

 Director      Number of Ordinary Shares issued for 2023 remuneration  Total number of ordinary shares held  Percentage of the Company's resulting issued share capital
 Jeff Needham  11,617                                                  27,961                                0.01%
 Andrew Unitt  11,970                                                  38,496                                0.01%

 

In addition, 19,913 shares have been issued to John Clarke.  John Clarke was
a Non-Executive Director until July 2023 and these shares represent 25 per
cent of his pro-rata remuneration for the period January to July 2023 in
accordance with his service agreement.

 

The shares element of the Non-Executive Directors' remuneration for 2024 will
be awarded at 27.10 pence per Ordinary Share, being the average closing
mid-market price of the last 10 trading days of 2023. The Non-Executive
Directors will receive these shares in January 2025.

 

Total Voting Rights

 

Application has been made to the London Stock Exchange and it is anticipated
that trading of the new Ordinary Shares will commence on AIM at 8:00am on 22
January 2024.

 

Immediately following the above issue, the Company will have 301,449,451
ordinary shares in issue, each carrying one voting right. Since the Company
currently holds no shares in treasury, the total number of voting rights in
the Company is therefore 301,449,541 and this figure may be used by
Shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change in
their interest in, the share capital of the Company under the FCA's Disclosure
Guidance and Transparency Rules.

Further details are contained within the notifications below, made in
accordance with Article 19 of the EU Market Abuse Regulation 596/2014. Full
details of the Non-Executive Directors' remuneration will be included in the
Company's Annual Report & Accounts.

ENDS

 

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: Investor.relations@futuramedical.com

Tel: +44 (0) 1483 685 670

www.Futuramedical.com (http://www.Futuramedical.com)

 

Nominated Adviser and Sole Broker:

Liberum

Phil Walker /Benjamin Cryer

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

Optimum Strategic Communications

Nick Bastin / Jonathan Edwards / Elena Bates

Email: futuramedical@optimumcomms.com (mailto:ziylo@optimumcomms.com)

Tel: +44 (0) 203 950 9144

Notes to editors

 

About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing
innovative products based on its proprietary, transdermal
DermaSys® technology.

 

MED3000, the Company's breakthrough treatment for erectile dysfunction ("ED")
has a unique evaporative mode of action and is clinically proven as an
effective topical treatment for adult men with ED, with a key claim of
"Helps you get an erection within 10 minutes". Eroxon® is available Over the
Counter ("OTC") without a doctor's prescription. www.eroxon.com
(http://www.eroxon.com/) .

 

MED3000 is being manufactured and commercialised under the brand name Eroxon®
and has been granted marketing authorisation by the FDA in the US, CE marked
in Europe, UKCA marked in the UK and is gaining regulatory approval in a
growing number of countries across the world. Futura has commercial agreements
with Haleon for the US market and Cooper Consumer Health for Europe.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(http://www.futuramedical.com/) .

 

 

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         Jeff Needham

 2    Reason for the notification
 a)   Position/status                                              Director/ PDMR

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Futura Medical plc

 b)   LEI                                                          21380053QLT46UNV2303

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument

                                                                   Ordinary shares of 0.2p each

      Identification code

                                                                   GB0033278473
 b)   Nature of the transaction                                    Issue of shares

 c)   Price(s) and volume(s)

Price(s)     Volume(s)

                                                                   51.50 pence  11,617
 d)   Aggregated information

      - Aggregated volume

                                                                   Not applicable

      - Price

 e)   Date of the transaction                                      16 January 2024

 f)   Place of the transaction                                     Outside of trading venue

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

 

Not applicable

 

 

e)

 

Date of the transaction

 

16 January 2024

f)

 

Place of the transaction

 

Outside of trading venue

 

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         Andrew Unitt

 2    Reason for the notification
 a)   Position/status                                              Director/ PDMR

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Futura Medical plc

 b)   LEI                                                          21380053QLT46UNV2303

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument

                                                                   Ordinary shares of 0.2p each

      Identification code

                                                                   GB0033278473
 b)   Nature of the transaction                                    Issue of shares

 c)   Price(s) and volume(s)

Price(s)     Volume(s)

                                                                   51.50 pence  11,970
 d)   Aggregated information

      - Aggregated volume

                                                                   Not applicable

      - Price

 e)   Date of the transaction                                      16 January 2024

 f)   Place of the transaction                                     Outside of trading venue

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

 

 

 

Not applicable

 

 

e)

 

Date of the transaction

 

16 January 2024

f)

 

Place of the transaction

 

Outside of trading venue

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRGPUAUGUPCGMQ